Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Central European Leukemia Study Group.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Central European Leukemia Study Group
ClinicalTrials.gov Identifier:
NCT00327262
First received: May 16, 2006
Last updated: June 16, 2006
Last verified: September 2005